3 results match your criteria: "Australia. Centre for Oncology Education and Research Translation (CONCERT)[Affiliation]"
Thulium oxide nanoparticles as radioenhancers for the treatment of metastatic cutaneous squamous cell carcinoma.
Phys Med Biol
November 2020
Illawarra Health and Medical Research Institute (IHMRI), Wollongong, NSW 2522, Australia. School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522, Australia. Centre for Oncology Education and Research Translation (CONCERT), NSW 2170, Australia.
Metastases from cutaneous squamous cell carcinoma (cSCC) occur in 2%-5% of cases. Surgery is the standard treatment, often combined with adjuvant radiotherapy. Concurrent carboplatin treatment with post-operative radiotherapy may be prescribed, although it has not shown benefit in recent clinical trials in high-risk cSCC patients.
View Article and Find Full Text PDF4D Monte Carlo dose calculations for pre-treatment quality assurance of VMAT SBRT: a phantom-based feasibility study.
Phys Med Biol
October 2019
Centre for Medical Radiation Physics (CMRP), University of Wollongong, Wollongong, NSW, Australia. Centre for Oncology Education and Research Translation (CONCERT), Wollongong, NSW, Australia. Ingham Institute for Applied Medical Research, Liverpool, NSW, Australia. Author to whom correspondence should be addressed.
Volumetric arc therapy (VMAT) for lung stereotactic body radiotherapy (SBRT) is challenging due to both breathing-induced motion and the dynamic components of the linear accelerator. In this study, a 4D Monte Carlo (4DMC) dose calculation method for VMAT SBRT is proposed and the feasibility of the method is evaluated. A rigidly-moving lung phantom was imaged using four dimensional computed tomography (4DCT).
View Article and Find Full Text PDFMolecular interactions of polo-like kinase 1 in human cancers.
J Clin Pathol
July 2016
Discipline of Pathology, School of Medicine, Western Sydney University, Sydney, Australia Centre for Oncology Education and Research Translation (CONCERT), Ingham Institute for Applied Medical Research, Sydney, Australia Cancer Pathology and Cell Biology Laboratory, Ingham Institute for Applied Medical Research, Sydney, Australia Molecular Medicine Research Group, School of Medicine, Western Sydney University, Sydney, Australia Department of Anatomical Pathology, Liverpool Hospital, Sydney, Australia South Western Sydney Clinical School, University of New South Wales, Sydney, Australia Cancer Pathology, Bosch Institute, University of Sydney, Sydney, Australia.
Polo-like kinase 1 (PLK1) is an essential protein in communicating cell-cycle progression and DNA damage. Overexpression of PLK1 has been validated as a marker for poor prognosis in many cancers. PLK1 knockdown decreases the survival of cancer cells.
View Article and Find Full Text PDF